Arrowhead Pharmaceuticals Quarterly Income Statement
NASDAQ: ARWRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Arrowhead Pharmaceuticals revenue and earnings
In the quarter ended Jun 30, 2026, Arrowhead Pharmaceuticals generated $75.3 million in revenue, up 171.0% from the same quarter a year earlier. Arrowhead Pharmaceuticals reported a net loss of $194.3 million, compared with a loss of $175.2 million a year earlier. Operating margin was -226.0%.
Diluted earnings per share came in at -$1.36.
Summary generated from market data by MetaCap's automated system. Methodology
Arrowhead Pharmaceuticals income statement (quarterly)
| Quarter (USD) | Q3 20262026-06-30 | Q2 20262026-03-31 | Q1 20262025-12-31 | Q4 20252025-09-30 | Q3 20252025-06-30 | Q2 20252025-03-31 | Q1 20252024-12-31 | Q4 20242024-09-30 | Q3 20242024-06-30 | Q2 20242024-03-31 | Q1 20242023-12-31 | Q4 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 75.25M | 73.74M | 264.03M | 256.47M | 27.77M | 542.71M | 2.50M | 0 | 0 | 0 | 3.55M | 16.10M |
| Revenue growth (YoY) | +171.02% | -86.41% | +10461.32% | — | — | — | -29.60% | -100.00% | -100.00% | -100.00% | -94.32% | -49.02% |
| Operating Expenses | 245.35M | 215.00M | 223.22M | 212.37M | 193.32M | 161.51M | 163.91M | 162.20M | 176.14M | 126.19M | 140.10M | 124.43M |
| Research & Development | 198.22M | 173.25M | 177.20M | 174.69M | 162.37M | 133.10M | 137.00M | 135.83M | 152.43M | 101.12M | 116.49M | 99.86M |
| Selling, General & Admin | 47.12M | 41.74M | — | — | 30.95M | 28.41M | — | — | — | — | — | — |
| Operating Income | -170.09M | -141.26M | 40.81M | 44.11M | -165.55M | 381.20M | -161.41M | -162.20M | -176.14M | -126.19M | -136.54M | -108.33M |
| Interest Expense | 24.56M | 23.85M | 22.50M | 21.69M | 24.38M | 21.64M | 21.65M | 14.65M | 5.09M | 7.24M | 5.37M | 5.26M |
| Other Income (Expense) | -8.81M | 3.69M | -12.54M | -7.99M | -13.54M | -11.59M | -13.70M | -10.60M | 2.16M | -805.00K | -2.14M | -660.00K |
| Pretax Income | -178.91M | -137.56M | 28.27M | 36.12M | -179.09M | 369.62M | -175.12M | -172.80M | -173.98M | -127.00M | -138.69M | -108.99M |
| Income Tax | 11.00K | 7.00K | 29.00K | 20.00M | -437.00K | 1.75M | 103.00K | 546.00K | 0 | 0 | -3.31M | 2.02M |
| Net Income | -194.28M | -132.73M | 30.81M | -23.75M | -175.24M | 370.44M | -173.09M | -170.54M | -170.79M | -125.30M | -132.86M | -109.68M |
| Net Income growth (YoY) | — | -135.83% | — | — | — | — | — | — | — | -357.42% | — | — |
| EPS (Basic) | -1.36 | -0.93 | 0.22 | -0.14 | -1.26 | 2.78 | -1.39 | -1.36 | -1.38 | -1.02 | -1.24 | -1.03 |
| EPS (Diluted) | -1.36 | -0.93 | 0.22 | -0.11 | -1.26 | 2.75 | -1.39 | -1.36 | -1.38 | -1.02 | -1.24 | -1.02 |
| Shares Outstanding (Basic) | 143.38M | 142.42M | 137.04M | — | 139.04M | 133.36M | 124.85M | — | 124.20M | 123.28M | 107.42M | — |
| Shares Outstanding (Diluted) | 143.38M | 142.42M | 140.71M | — | 139.04M | 134.48M | 124.85M | — | 124.20M | 123.28M | 107.42M | — |
| EBITDA | -163.89M | -135.36M | 46.81M | 50.11M | -159.75M | 386.80M | -156.61M | -157.60M | -171.74M | -122.09M | -132.75M | -105.03M |
| Operating Margin | -226.03% | -191.57% | 15.46% | 17.20% | -596.21% | 70.24% | -6456.48% | — | — | — | -3845.25% | -672.98% |
| Net Margin | -258.17% | -180.01% | 11.67% | -9.26% | -631.11% | 68.26% | -6923.40% | — | — | — | -3741.59% | -681.36% |
This table shows 12 quarterly periods of Arrowhead Pharmaceuticals's income statement, from Q3 2026 back to Q4 2023, across 17 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow ARWR's reporting calendar. What is a income statement?